var data={"title":"Ethambutol: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ethambutol: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6149?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">see &quot;Ethambutol: Drug information&quot;</a> and <a href=\"topic.htm?path=ethambutol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ethambutol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520118\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Myambutol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168049\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Etibi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047287\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antitubercular Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047281\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">see &quot;Ethambutol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tuberculosis, active treatment (excluding meningitis):</b> <b>Note</b>: Recommendations often change due to epidemiology (resistance) and emerging information; consult CDC and WHO for current recommendations, as appropriate<b>.</b> Always use as part of a multidrug regimen. Any regimens using less than once daily dosing should administer dosing as directly observed therapy (DOT). Treatment regimens for pulmonary tuberculosis consist of an initial 2-month intensive phase of a 4-drug regimen, followed by a continuation phase of an additional 4 to 7 months of isoniazid and rifampin. Ethambutol frequency and dosing differs depending on treatment regimen selected; consult current drug-sensitive TB guidelines for detailed information (ATS/CDC/IDSA [Nahid 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>ATS/CDC/IDSA Recommendations</i> (ATS/CDC/IDSA [Nahid 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Once daily or 5-times-weekly (DOT):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents &lt;15 years, weighing &lt;40 kg: Oral: 20 mg/kg/dose once daily or 5-times-weekly DOT, suggested range: 15 to 25 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &lt;15 years weighing &ge;40 kg or Adolescents &ge;15 years: <b>Note:</b> Doses should be based on <b>lean</b> body weight for patients within a normal weight range for their height (optimal dosing for obese patients has not been established): Oral: Weight-band dosing for whole tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">40 to 55 kg: 800 mg (14.5 to 20 mg/kg/dose) once daily or 5-times-weekly (DOT)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">56 to 75 kg: 1,200 mg (16 to 21.4 mg/kg/dose) once daily or 5-times-weekly (DOT)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">76 to 90 kg: 1,600 mg (17.8 to 21.1 mg/kg/dose) once daily or 5-times-weekly (DOT)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Three-times-weekly DOT: </i>\n      <b>Note:</b> Although suggested dosing based on experience with twice-weekly regimen; experts suggest 3-times-weekly regimens are more effective than twice weekly DOT regimens; ethambutol-containing 3-times-weekly DOT may be used as part of an intensive phase; consult guidelines for specific information</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents, weighing &lt;40 kg: Oral: 50 mg/kg/dose 3-times-weekly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents weighing &ge;40 kg: <b>Note: </b>Doses should be based on <b>lean</b> body weight for patients within a normal weight range for their height (optimal dosing for obese patients has not been established); Oral: Weight-band dosing for whole tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">40 to 55 kg: 1,200 mg (21.8 to 30 mg/kg/dose) 3-times-weekly</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">56 to 75 kg: 2,000 mg (26.7 to 35.7 mg/kg/dose) 3-times-weekly</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">76 to 90 kg: 2,400 mg (26.7 to 31.6 mg/kg/dose) 3-times-weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Twice weekly DOT: </i>\n      <b>Note:</b> Regimen not generally recommended; do not use in HIV patients or those with smear-positive and/or cavitary disease. This therapy should only be used following completion of a 2-week intensive phase once daily (or 5-times-weekly) regimen. Missed doses result in the equivalent of once-weekly dosing which has been shown to be inferior and is associated with treatment failure, relapse, and development of drug resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents &lt;15 years, weighing &lt;40 kg: Oral: 50 mg/kg/dose twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &lt;15 years weighing &ge;40 kg or Adolescents &ge;15 years: <b>Note: </b>Doses should be based on <b>lean</b> body weight for patients within a normal weight range for their height (optimal dosing for obese patients has not been established); Oral: Weight-band dosing for whole tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">40 to 55 kg: 2,000 mg (36.4 to 50 mg/kg/dose) twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">56 to 75 kg: 2,800 mg (37.3 to 50 mg/kg/dose) twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">76 to 90 kg: 4,000 mg (44.4 to 52.6 mg/kg/dose) twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Mycobacterium avium</i></b>\n      <b> complex (MAC) in HIV-exposed/-positive:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: Oral: 15 to 25 mg/kg/dose once daily; maximum dose: 2,500 mg/dose; in combination with clarithromycin (or azithromycin); for severe disease add rifabutin (HHS [pediatric OI 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Oral: 15 mg/kg/dose once daily in combination with clarithromycin (or azithromycin) (HHS [adult OI 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chronic suppressive therapy</i>\n      <b>:</b> Infants and Children: Oral: 15 to 25 mg/kg/dose once daily; maximum dose: 2,500 mg/dose with clarithromycin (or azithromycin) with or without rifabutin (HHS [pediatric OI 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nontuberculous mycobacterial infection (eg, <i>m. kansasii</i>):</b> Limited data available: Infants, Children, and Adolescents: 15 to 25 mg/kg/dose once daily; maximum dose: 2,500 mg/dose (Bradley 2016; <i>Red Book</i> [AAP] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Disseminated </b> <b><i>Mycobacterium avium </i></b> <b>(MAC) treatment in patients with advanced HIV infection (ATS/IDSA guidelines 2007):</b> Oral: 15 mg/kg ethambutol in combination with clarithromycin or azithromycin with/without rifabutin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tuberculosis, active:</b> Oral: FDA approved labeling: Initial: 15 mg/kg once daily (maximum dose: 1.5 g); Re-treatment (previous antituberculosis therapy): 25 mg/kg once daily (maximum dose: 2.5 g) for 60 days or until bacteriologic smears and cultures become negative, followed by 15 mg/kg daily</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">Suggested doses by lean body weight (CDC 2003):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Daily therapy: 15 to 25 mg/kg (maximum dose: 1.6 g)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">40 to 55 kg: 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">56 to 75 kg: 1,200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">76 to 90 kg: 1,600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Twice weekly directly observed therapy (DOT): 50 mg/kg (maximum dose: 4 g)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">40 to 55 kg: 2,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">56 to 75 kg: 2,800 mg</p>\n    <p style=\"text-indent:0em;margin-left:8em;\">76 to 90 kg: 4,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Three times weekly DOT: 25 to 30 mg/kg (maximum dose: 2.4 g)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">40 to 55 kg: 1,200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">56 to 75 kg: 2,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">76 to 90 kg: 2,400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Used as part of a multidrug regimen. Treatment regimens consist of an initial 2 month phase, followed by a continuation phase of 4 or 7 additional months; frequency of dosing may differ depending on phase of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nontuberculous mycobacterium </b>\n      <b>\n        <i>(M. kansasii)</i></b>\n      <b> (off-label use; ATS/IDSA guidelines 2007):</b> Oral: 15 mg/kg/day ethambutol for duration to include 12 months of culture-negative sputum; typically used in combination with rifampin and isoniazid; <b>Note:</b> Previous recommendations stated to use 25 mg/kg/day for the initial 2 months of therapy; however, IDSA guidelines state this may be unnecessary given the success of rifampin-based regimens with ethambutol 15 mg/kg/day or omitted altogether.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling: </i>Reduce dosing as determined by serum levels (specific dosing adjustments not provided); primarily renally excreted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ATS/CDC/IDSA Recommendation: Treatment drug-susceptible TB (Nahid 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute: 20 to 25 mg/kg/dose 3-times-weekly (do not administer daily dosing)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: 20 to 25 mg/kg/dose 3-times-weekly (do not administer daily dosing); administer after dialysis if given on a dialysis day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aronoff 2007:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 50 mL/minute: Administer every 24 to 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Slightly dialyzable (5% to 20%): Administer dose postdialysis</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis: Dose for CrCl &lt;10 mL/minute: Administer every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous arteriovenous or venovenous hemofiltration: Dose for CrCl 10 to 50 mL/minute: Administer every 24 to 36 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168024\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myambutol: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myambutol: 400 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168009\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047290\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with or without food; if GI upset occurs, administer with food. Tablet may be pulverized and mixed with apple juice or apple sauce. Do not mix with other juices or syrups since they do not mask ethambutol's bitter taste or are not stable. Administer ethambutol at least 4 hours before aluminum hydroxide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168043\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047289\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of pulmonary tuberculosis (FDA approved in ages &ge;13 years and adults); has also been used for the treatment of other mycobacterial diseases in conjunction with other antimycobacterial agents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168094\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myambutol may be confused with Nembutal</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168092\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Myocarditis, pericarditis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion, disorientation, dizziness, hallucination, headache, malaise, peripheral neuritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatitis, erythema multiforme, exfoliative dermatitis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acute gout attack, hyperuricemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, gastric distress, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Eosinophilia, leukopenia, lymphadenopathy, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, hepatitis, hepatotoxicity (possibly related to concurrent therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, anaphylactoid reaction, hypersensitivity reaction (syndrome includes cutaneous reactions, eosinophilia, and organ-specific inflammation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Color blindness, decreased visual acuity, optic neuritis, scotoma, visual disturbance (usually reversible with discontinuation; irreversible blindness has been described)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Nephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pneumonitis, pulmonary infiltrates (with or without eosinophilia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168030\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ethambutol or any component of the formulation; optic neuritis (risk vs benefit decision); use in young children, unconscious patients, or any other patient who may be unable to discern and report visual changes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168013\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic toxicity: Has been reported, possibly due to concurrent therapy. Monitor liver function prior to and during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Optic neuritis: May cause optic neuritis (unilateral or bilateral), resulting in decreased visual acuity or other vision changes. Discontinue promptly in patients with changes in vision, color blindness, or visual defects (effects normally reversible, but reversal may require up to a year). Irreversible blindness has been reported. Monitor visual acuity prior to and during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ocular disease: Evaluation of visual acuity changes may be more difficult in patients with cataracts, optic neuritis, diabetic retinopathy, and inflammatory conditions of the eye; consideration should be given to whether or not visual changes are related to disease progression or effects of therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage modification recommended. Monitor renal function prior to and during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Use only in children whose visual acuity can accurately be determined and monitored (not recommended for use in children &lt;13 years of age unless the benefit outweighs the risk).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299290\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168018\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13286&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: May decrease the serum concentration of Ethambutol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168020\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168033\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Ophthalmic abnormalities have been reported in infants born to women receiving ethambutol as a component of antituberculous therapy. Due to the risk of untreated tuberculosis to the mother and fetus, treatment is recommended when the probability of maternal disease is moderate to high. Ethambutol is one of the recommended agents to treat tuberculosis in pregnant women (Nahid 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047286\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monthly examination of visual acuity and color discrimination in patients receiving &gt;15 mg/kg/day; periodic renal, hepatic, and hematologic function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168012\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits arabinosyl transferase resulting in impaired mycobacterial cell wall synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168029\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: ~80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely throughout body; concentrated in kidneys, lungs, saliva, and red blood cells</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF:blood level ratio: Normal meninges: 0%; Inflamed meninges: 25%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 20% to 30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (20%) to inactive metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 2.5 to 3.6 hours; End-stage renal disease: 7 to 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~50% as unchanged drug, 8% to 15% as metabolites); feces (~20% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168032\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ethambutol HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $52.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $156.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Myambutol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $57.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $93.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168036\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Afimocil (KW, QA);</li>\n      <li>Ambutol (MY);</li>\n      <li>Amiobutols (LV);</li>\n      <li>Arbutol (ID);</li>\n      <li>Bacbutol (ID);</li>\n      <li>Clobutol (PT);</li>\n      <li>Combutol (IN);</li>\n      <li>Dexambutol (FR);</li>\n      <li>E-Butol (SG);</li>\n      <li>Ebutol (SG, TW);</li>\n      <li>Ecox (CO, ET, LK, MY);</li>\n      <li>Ekoks (UA);</li>\n      <li>EMB (DE);</li>\n      <li>EMB-Fatol (HK);</li>\n      <li>Etambutol (BG, HR);</li>\n      <li>Etambutol Northia (AR);</li>\n      <li>Etambutol Richet (AR);</li>\n      <li>Etambutol Richmond (AR);</li>\n      <li>Etapiam (IT);</li>\n      <li>ETH Ciba 400 (ID);</li>\n      <li>Etham (BD, TH);</li>\n      <li>Ethambin-PIN (PH);</li>\n      <li>Ethambutol (PL);</li>\n      <li>Ethbutol (TH);</li>\n      <li>Etibi (AT, ID, IT);</li>\n      <li>Eubotol (VN);</li>\n      <li>Inbutol (UA);</li>\n      <li>Interbutol (PH);</li>\n      <li>Kombutol (UA);</li>\n      <li>Lambutol (TH);</li>\n      <li>Litamol (VN);</li>\n      <li>Manzida (MX);</li>\n      <li>Myambutol (AE, AT, AU, BB, BE, BF, BJ, CH, CI, DE, DK, ES, ET, FR, GB, GH, GM, GN, GR, IN, KE, KR, KW, LR, LU, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, PK, PT, QA, SA, SC, SD, SE, SI, SL, SN, TH, TN, TZ, UG, ZM, ZW);</li>\n      <li>Mycobac (BD);</li>\n      <li>Mycobutol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Oributol (FI);</li>\n      <li>Purderal (ZA);</li>\n      <li>Riotol (TW);</li>\n      <li>Servambutol (PE);</li>\n      <li>Stambutol (FI);</li>\n      <li>Sural (BD, CZ, HN, HU);</li>\n      <li>Tambutol (KR);</li>\n      <li>Thamtol (ET);</li>\n      <li>Thural (BD);</li>\n      <li>Tibigon (ID);</li>\n      <li>Tibitol (ID, IN);</li>\n      <li>Tibutol (PE);</li>\n      <li>Tobutol (TH);</li>\n      <li>Winbutol (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo; <i>Pediatrics</i>, 1992, 89(1):161-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/ 1728006 /pubmed\" target=\"_blank\" id=\" 1728006 \"> 1728006 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society, CDC, and Infectious Diseases Society of America, &quot;Treatment of Tuberculosis,&quot; <i>MMWR Recomm Rep</i>, 2003, 52(RR-11):1-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/12836625/pubmed\" target=\"_blank\" id=\"12836625\">12836625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ethambutol tablet [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graham SM, Bell DJ, Nyirongo S, et al, &quot;Low Levels of Pyrazinamide and Ethambutol in Children With Tuberculosis and Impact of Age, Nutritional Status, and Human Immunodeficiency Virus Infection,&quot; <i>Antimicrob Agents Chemother</i>, 2006, 50(2):407-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/16436690/pubmed\" target=\"_blank\" id=\"16436690\">16436690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griffith DE, Aksamit T, Brown-Elliott BA, et al, &quot;An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases,&quot; <i>Am J Respir Crit Care Med</i>, 2007, 175(4):367-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/17277290/pubmed\" target=\"_blank\" id=\"17277290\">17277290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2016. Available at <a href=\"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0\" target=\"_blank\">https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill S, Regondi I, Grzemska M, et al, &quot;Children and Tuberculosis Medicines: Bridging the Research Gap,&quot; <i>Bull World Health Organ</i>, 2008, 86(9):658.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/18797634/pubmed\" target=\"_blank\" id=\"18797634\">18797634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/27516382/pubmed\" target=\"_blank\" id=\"27516382\">27516382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14:455-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/7667049/pubmed\" target=\"_blank\" id=\"7667049\">7667049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tran JH and Montakantikul P, &ldquo;The Safety of Antituberculosis Medications During Breastfeeding,&rdquo; <i>J Hum Lact</i>, 1998, 14(4):337-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-pediatric-drug-information/abstract-text/10205455/pubmed\" target=\"_blank\" id=\"10205455\">10205455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Treatment of tuberculoisis guidelines. 4th edition. 2010.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13286 Version 107.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520118\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F168049\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047287\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047281\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F168024\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F168009\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047290\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F168043\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047289\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F168094\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F168092\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F168030\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F168013\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299290\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F168018\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F168020\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F168033\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047286\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F168012\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F168029\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F168032\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F168036\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13286|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">Ethambutol: Drug information</a></li><li><a href=\"topic.htm?path=ethambutol-patient-drug-information\" class=\"drug drug_patient\">Ethambutol: Patient drug information</a></li></ul></div></div>","javascript":null}